Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. more
Time Frame | XLO | Sector | S&P500 |
---|---|---|---|
1-Week Return | -16.68% | -2.06% | -0.55% |
1-Month Return | -10.85% | -1.92% | 2.72% |
3-Month Return | 6.32% | -10.4% | 7.66% |
6-Month Return | -8.5% | -4.6% | 10.15% |
1-Year Return | 20.35% | 4.06% | 27.53% |
3-Year Return | -92.59% | 1.94% | 32.31% |
5-Year Return | -94.58% | 36.48% | 89.2% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 240.00K | 1.06M | 1.50M | 1.85M | 1.90M | [{"date":"2019-12-31","value":12.63,"profit":true},{"date":"2020-12-31","value":56.05,"profit":true},{"date":"2021-12-31","value":78.89,"profit":true},{"date":"2022-12-31","value":97.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (240.00K) | (1.06M) | (1.50M) | (1.85M) | (1.90M) | [{"date":"2019-12-31","value":-24000000,"profit":false},{"date":"2020-12-31","value":-106500000,"profit":false},{"date":"2021-12-31","value":-149900000,"profit":false},{"date":"2022-12-31","value":-184700000,"profit":false},{"date":"2023-12-31","value":-190000000,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 19.03M | 54.56M | 75.04M | 89.15M | 79.13M | [{"date":"2019-12-31","value":21.34,"profit":true},{"date":"2020-12-31","value":61.2,"profit":true},{"date":"2021-12-31","value":84.18,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":88.76,"profit":true}] |
Operating Income | (19.03M) | (54.56M) | (75.04M) | (89.15M) | (79.13M) | [{"date":"2019-12-31","value":-1902700000,"profit":false},{"date":"2020-12-31","value":-5456300000,"profit":false},{"date":"2021-12-31","value":-7504400000,"profit":false},{"date":"2022-12-31","value":-8914900000,"profit":false},{"date":"2023-12-31","value":-7913300000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (17.31M) | (55.22M) | (75.80M) | (88.22M) | (76.40M) | [{"date":"2019-12-31","value":-1731100000,"profit":false},{"date":"2020-12-31","value":-5521900000,"profit":false},{"date":"2021-12-31","value":-7580000000,"profit":false},{"date":"2022-12-31","value":-8822200000,"profit":false},{"date":"2023-12-31","value":-7640400000,"profit":false}] |
Income Taxes | (1.72M) | 858.70K | (1.50M) | (927.00K) | (927.00K) | [{"date":"2019-12-31","value":-199.84,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-174.57,"profit":false},{"date":"2022-12-31","value":-107.95,"profit":false},{"date":"2023-12-31","value":-107.95,"profit":false}] |
Income After Taxes | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (17.31M) | (55.22M) | (75.80M) | (88.22M) | (81.22M) | [{"date":"2019-12-31","value":-1731100000,"profit":false},{"date":"2020-12-31","value":-5521900000,"profit":false},{"date":"2021-12-31","value":-7580000000,"profit":false},{"date":"2022-12-31","value":-8822200000,"profit":false},{"date":"2023-12-31","value":-8121500000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (17.31M) | (55.22M) | (74.30M) | (87.30M) | (76.40M) | [{"date":"2019-12-31","value":-1731100000,"profit":false},{"date":"2020-12-31","value":-5521900000,"profit":false},{"date":"2021-12-31","value":-7430100000,"profit":false},{"date":"2022-12-31","value":-8729500000,"profit":false},{"date":"2023-12-31","value":-7640400000,"profit":false}] |
EPS (Diluted) | (19.83) | (107.37) | (25.16) | (3.22) | (2.78) | [{"date":"2019-12-31","value":-1983.34,"profit":false},{"date":"2020-12-31","value":-10736.77,"profit":false},{"date":"2021-12-31","value":-2516,"profit":false},{"date":"2022-12-31","value":-322,"profit":false},{"date":"2023-12-31","value":-278,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
XLO | |
---|---|
Cash Ratio | 1.61 |
Current Ratio | 1.67 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
XLO | |
---|---|
ROA (LTM) | -52.58% |
ROE (LTM) | -170.96% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
XLO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.72 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.28 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
XLO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 8.24 |
P/B | 1.80 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Xilio Development Inc (XLO) share price today is $0.8665
Yes, Indians can buy shares of Xilio Development Inc (XLO) on Vested. To buy Xilio Development Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in XLO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Xilio Development Inc (XLO) via the Vested app. You can start investing in Xilio Development Inc (XLO) with a minimum investment of $1.
You can invest in shares of Xilio Development Inc (XLO) via Vested in three simple steps:
The 52-week high price of Xilio Development Inc (XLO) is $1.63. The 52-week low price of Xilio Development Inc (XLO) is $0.5.
The price-to-earnings (P/E) ratio of Xilio Development Inc (XLO) is
The price-to-book (P/B) ratio of Xilio Development Inc (XLO) is 1.80
The dividend yield of Xilio Development Inc (XLO) is 0.00%
The market capitalization of Xilio Development Inc (XLO) is $40.76M
The stock symbol (or ticker) of Xilio Development Inc is XLO